Study Finds Diabetes, Heart Disease Risk Drops Among Psychedelics Users

October 22, 2021 12:20:10

A new study has found that individuals who have consumed a psychedelic substance at least once in their lives have decreased chances of developing diabetes or heart disease. The study was reported in the “Scientific Reports” journal.

University of Oxford’s Otto Simonsson, the author of the study, stated that prior research had discovered links between lower chances of having hypertension and being obese or overweight and lifetime use of classic psychedelics, noting that hypertension and obesity were cardio-metabolic disease risk factors. Simonsson explained that the purpose of the research was to find the association between cardio-metabolic ailments such as heart disease and diabetes and lifetime use of classic psychedelics.

Earlier this year, the researchers had published an article in the “Journal of Psychopharmacology” arguing that psychedelics such as psilocybin could help promote positive lifestyle changes that were good for an individual’s overall health. In the article, the researchers noted that the use of psychedelics had also been linked to impromptu changes in health-related behaviors, linked to exercising more and decreased consumption of alcohol.

For their study, the researchers assessed data from more than 375,000 individuals who had taken part in the National Survey on Drug Use and Health, in order to examine the relationship between physical health and the use of psychedelics. The National Survey on Drug Use and Health is a survey conducted annually sponsored by the Department of Health and Human Services in the United States.

Survey participants were asked whether they had used classic psychedelics, including psilocybin, peyote, mescaline, LSD, ayahuasca and DMT. This is in addition to being asked if they had been diagnosed with diabetes or heart disease in the past year.

The researchers discovered that the prevalence of diabetes and heart disease was lower among users of psychedelics, after controlling for the use of other drug types, engagement in risky behavior, education levels, yearly household income, race, marital status, gender and age. For instance, in comparison to the 7.6% who had never used a psychedelic only 4% of those who had used psychedelics had been diagnosed with diabetes.

Additionally, compared to the 4.5% who admitted to having never used a psychedelic substance, only 2.2% of those who had used a psychedelic reported that they had been diagnosed with heart disease.

In an interview, Simonsson noted that these discoveries suggest that lifetime use of classic psychedelics was linked to lower chances of having had diabetes or heart disease. The researchers note that their findings highlight the need for more research that explores the association between cardio-metabolic health and psychedelic substances.

Such research provides additional proof that companies such as Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) that operate a psychedelic wellness platform and licensed ketamine infusion clinics are offering something which can enrich the health and well-being of community members.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.